Innate Pharma S.A. (NASDAQ:IPHA) Sees Significant Increase in Short Interest

Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 461,400 shares, an increase of 199.2% from the February 13th total of 154,200 shares. Currently, 0.8% of the company's stock are short sold. Based on an average trading volume of 677,300 shares, the days-to-cover ratio is presently 0.7 days.

Innate Pharma Trading Down 1.0 %

NASDAQ IPHA traded down $0.02 during trading hours on Thursday, hitting $1.99. 8,210 shares of the stock were exchanged, compared to its average volume of 299,653. Innate Pharma has a 12-month low of $1.29 and a 12-month high of $3.51. The stock has a 50-day moving average of $1.94 and a 200 day moving average of $1.96.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $11.50 price objective on shares of Innate Pharma in a report on Thursday, February 6th.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads